Opus Genetics (IRD) Jefferies Global Healthcare Conference 2026 summary

Key clinical programs and pipeline

• Seven gene therapy programs targeting inherited retinal diseases are advancing in parallel, leveraging rapid clinical timelines and capital efficiency.

• LCA5 and BEST1 are the most advanced, with pivotal and first-in-human data expected in the near term; LCA5 phase III design is being finalized with the FDA.

• BEST1 targets a population of about 8,500 US patients, with three-month data on the first five patients expected in September.

• LCA5, a rare childhood blindness disorder, has shown normalization of cone photoreceptor sensitivity and dramatic improvements in vision in early trials.

• Other programs (RHO, RDH12, MERTK, NMNAT1, CNGB1) are progressing toward clinical trials, with MERTK receiving funding from the UAE Department of Health.

Clinical results and trial design

• Subretinal injection delivers gene therapy directly to photoreceptors, minimizing off-target effects and enabling precise treatment.

• Early LCA5 trial data show rapid and significant improvements in visual function, including patients gaining the ability to see letters for the first time.

• BEST1 phase I/II trial demonstrated a 12-letter vision gain in a severe patient, with further data to be reported soon.

• Trials are designed for efficiency, allowing quick progression to pivotal studies or dose escalation based on early efficacy signals.

• FDA-approvable endpoints such as microperimetry and full-field stimulus threshold are being used to support regulatory submissions.

Financial outlook and commercialization

• Programs are capital efficient, with an estimated $30 million and three years from IND to BLA.

• Commercial partnership for a presbyopia eye drop provides up to $100 million in milestones and double-digit royalties, with a PDUFA date in October.

• Cash runway extends into 2029, supporting multiple data readouts and potential first approval.

• Ex-US opportunities, especially in the Middle East and EU, could significantly increase market potential.

• Pricing expectations are benchmarked to LUXTURNA and other gene therapies, suggesting high value per patient.